Gastric cancer (GC) is a main cause of cancer death in the world, and improving the chemotherapy sensitivity can enhance the chemotherapy efficacy of GC. The study objective is to explore the differential KIF18B expression in GC and its effect on GC chemotherapy sensitivity. The KIF18B expression in GC tissues and adjacent normal tissues was analyzed by real-time quantitative polymerase chain reaction. The relationship between differential KIF18B expression and different clinicopathological features was detected. It was found that KIF18B was highly expressed in GC tissues, and KIF18B expression was differential in patients with different clinicopathological features. The upregulation of KIF18B has a positive correlation with the poor therapeutic effect and high KIF18 was associated with lower 3-year overall survival and disease-free survival. The KIF18B-downregulated NCI-N87 cells were constructed and tested by cell counting kit-8 assay and colony formation. Cell migration and invasion were detected by Transwell assay. The xenograft tumor model was established to observe the effect of KIF18B on the efficacy of chemotherapy. The upregulation of KIF18B reduced the chemotherapy sensitivity of GC cells and enhanced their proliferation, migration, and invasion. Silencing KIF18B inhibited tumor growth and promoted chemotherapy efficacy in vivo. In summary, KIF18B inhibitor may have a potential function for improving the efficacy of chemotherapy in GC.

中文翻译：

---

KIF18B在胃癌中的差异表达及其在化疗敏感性中的作用

胃癌（GC）是全球癌症死亡的主要原因，提高化疗敏感性可以增强GC的化疗疗效。本研究的目的是探讨胃癌中KIF18B的差异表达及其对胃癌化疗敏感性的影响。采用实时定量聚合酶链式反应分析胃癌组织及癌旁正常组织中KIF18B的表达情况。检测KIF18B差异表达与不同临床病理特征之间的关系。结果发现KIF18B在GC组织中高表达,且不同临床病理特征患者中KIF18B表达存在差异。KIF18B 的上调与较差的治疗效果呈正相关，高 KIF18 与较低的 3 年总生存率和无病生存率相关。构建 KIF18B 下调的 NCI-N87 细胞，并通过细胞计数试剂盒 8 测定和集落形成进行测试。Transwell实验检测细胞迁移和侵袭。建立异种移植瘤模型，观察KIF18B对化疗疗效的影响。KIF18B 的上调降低了 GC 细胞的化疗敏感性，并增强了其增殖、迁移和侵袭。沉默KIF18B可抑制肿瘤生长并提高体内化疗效果。综上所述，KIF18B抑制剂可能具有提高GC化疗疗效的潜在作用。